C9orf72 and amyotrophic lateral sclerosis: Targeting of C9ORF72‐S by antisense oligonucleotides (ASOs) and of the G‐quadruplex structure formed by C9ORF72‐S by specific binding molecules have been explored as therapeutic strategies for C9‐ALS (Donnelly et al., 2013; Jiang, Zhu, et al., 2016; Lagier‐Tourenne et al., 2013; Simone et al., 2018; Zamiri et al., 2014; Zhang et al., 2015).